[144] VERTEX PHARMACEUTICALS INC / MA SEC Filing

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) Form 144 notice reports a proposed sale of 694 shares of common stock through Fidelity Brokerage Services, with an approximate aggregate market value of $280,521.74 and an approximate sale date of 10/02/2025 on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting from the issuer and were paid as compensation. The filer reports no other sales in the past three months and makes the required representation that no undisclosed material adverse information is known.

Positive

• Disclosure complies with Rule 144, including acquisition date, nature of acquisition, broker, and approximate sale date
• Securities originated from restricted stock vesting, and payment was reported as compensation

Negative

• None.

Insights

Securities Analyst

TL;DR: Small, routine insider sale from restricted stock vesting; immaterial to outstanding shares.

The notice documents a planned disposal of 694 shares valued at about $280.5k executed through Fidelity with an approximate sale date one day after vesting. Relative to the reported 256,390,651 shares outstanding, this position is de minimis and unlikely to affect market supply or company valuation. The transaction appears to be a compensation-related vesting event followed by a sale, which is common practice for insiders monetizing small grants. The filing includes the standard Rule 144 representation and reports no other insider sales in the prior three months.

Corporate Governance Specialist

TL;DR: Procedural disclosure consistent with compliance; no red flags in the filing.

This Form 144 provides the necessary disclosures: acquisition date, nature of acquisition (restricted stock vesting), broker details, and an approximate sale date. The filer affirms absence of undisclosed material information and reports no aggregated selling over the prior three months. From a governance standpoint, the timing and disclosure meet routine regulatory expectations and do not indicate governance or compliance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	694	280521.74	256390651	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Restricted Stock Vesting	Issuer			694	10/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the VRTX Form 144 report?

The filing reports a proposed sale of 694 shares of common stock acquired via restricted stock vesting on 10/01/2025, with an approximate aggregate market value of $280,521.74 and an approximate sale date of 10/02/2025.

Through which broker will the VRTX shares be sold?

The shares are to be sold through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) on the NASDAQ.

Does the filing report other insider sales in the past three months for VRTX?

No. The Form 144 indicates "Nothing to Report" for securities sold during the past three months.

What was the nature of acquisition for the shares in this Form 144?

The shares were acquired on 10/01/2025 as restricted stock vesting from the issuer and were considered compensation.

How material is this sale relative to Vertex's outstanding shares?

The filing shows 694 shares versus 256,390,651 shares outstanding, indicating the position is de minimis in size.